Snap Inc (NYSE: SNAP) launched My AI, a new chatbot running the latest version of OpenAI's ChatGPT technology customized for Snapchat. My AI is available as an experimental feature for Snapchat+ subscribers, rolling out this week. My AI can recommend birthday gift ideas, plan a hiking trip, suggest a dinner recipe, or even write a haiku about cheese. Snapchat users can give it a name and customize the wallpaper for Chat. However, My AI is prone to hallucination, and users can trick it into sayin Read More...
Benzinga
Why Reata Pharmaceuticals Shares Are Falling Monday?
According to various reports, the FDA’s neuroscience expert Billy Dunn is leaving the agency after more than 15 years, effective immediately. Dunn presided over the controversial approval of Biogen Inc’s (NASDAQ: BIIB) Alzheimer’s disease treatment, Aduhelm (aducanumab). Dunn, 53, is retiring from the agency to “explore other opportunities,” according to an internal FDA email. Dunn notified agency officials Friday, according to a person with knowledge of the situation. Reata Pharmaceuticals Inc
